Curis Pivots Toward CLL: A Micro-Cap's Dual-Blockade Thesis Gets a Bigger Arena

The $19M biotech is betting its registrational PCNSL story is a template for a CLL paradigm shift, but a razor-thin balance sheet makes the next five months a binary test.

CRIS · Earnings Call · 2026-05-13

An Ultra-Orphan Play Grows Up

Curis has long been the poster child for ultra-orphan drug development: a single-arm registrational study in primary CNS lymphoma (PCNSL) with a 30–40 patient target. But the first-quarter call revealed a deliberate broadening of the franchise. The company is now pushing into chronic lymphocytic leukemia (CLL), the largest NHL subtype, with the same dual blockade mechanism that has produced complete remissions in PCNSL. Management's thesis is consistent: emavusertib blocks the TLR pathway driving NF-κB, and adding it to a BTK inhibitor (which blocks the BCR pathway) yields deeper responses. In CLL, the goal is to convert partial responders on BTK monotherapy into complete remissions or undetectable MRD. “If we are successful, adding emavusertib to BTKi could change the treatment paradigm in CLL, reducing the risk of developing a treatment-resistant mutation and improving a patient's overall quality of life.” — James Dentzer, Chief Executive Officer · 2026-05-13 CEO Jim Dentzer's ambition is clear. The proof-of-concept design targets patients who have plateaued on a BTK inhibitor. Enrollment is on track for the first five patients to be dosed by mid-2026. “we're obviously very, very confident that we are hitting our target on track” — James Dentzer, Chief Executive Officer · 2026-05-13, said Dentzer. Chief Medical Officer Ahmed Hamdy added differentiation from existing combos: “we feel that this can really be a paradigm shift in the treatment of CLL in a combination setting when we inhibit 2 nodes in the main pathway that is activating the disease.” — Ahmed Hamdy, Medical or Clinical Expert (likely a physician or clinical lead) · 2026-05-13 This is not a new idea. On the March 2026 call, Dentzer already laid out the strategic priority: “Right now, we have a dual-pronged strategy where we are pushing forward very aggressively in PCNSL... as well as CLL, which is inarguably the largest.” — James E. Dentzer, Chief Executive Officer · 2026-03-19 The CLL study plans were sketched as far back as late 2025, with a 40-patient design and hopes of seeing a signal early. As Dentzer put it on that call:

we are anticipating a study design at this point in time that anticipates 40 patients. But of course, as we saw in PCNSL, the unmet need is so clear, we're hoping to be able to see a signal long before we get to that point.
James Dentzer, Chief Executive Officer · 2025-11-07

The Financial Tightrope

Expanding into CLL comes at a steep cost for a company with a microscopic market cap. Net loss for Q1 2026 was $24.2 million, a 128% year-over-year increase, driven primarily by a non-cash change in fair value of warrant liabilities. The cash position is thin. Effective net cash stood at just $6 million as of March 31, 2026, and cash runway is under two quarters.Cash runway was 1.7x, down 39% year-over-year. The company is leaning on a single near-term trigger: the January 2026 PIPE financing included Series B warrants that can be exercised for up to $20.2 million upon the public announcement of dosing the fifth CLL patient. CFO Diantha Duvall laid out the math: “Curis' cash and cash equivalents as of March 31, 2026, of $15 million, together with anticipated gross proceeds of up to an additional $20.2 million from the exercise of the January 2026 PIPE financing Series B warrants upon the public announcement of dosing of the fifth CLL patient in our TakeAim CLL study expected later this year should enable the company's planned operations into the second half of '27.” — Diantha Duvall, Chief Financial Officer · 2026-05-13 This is a more fragile balance sheet than the prior call suggested. In March, Dentzer said the January financing "puts us on a very solid course," but a missed enrollment milestone for the fifth CLL patient would force dilutive capital raises or asset sales. The MRD negative goal is ambitious, but the financial stringency means every quarter without the warrant-extension catalyst tightens the noose.

What the Tape Says

The market has already voted on the story. The stock is up 216% in the last 90 days, yet it sits 73% below its July peak. That kind of volatility suggests traders are positioning for the CLL interim data at ASH in December, while simultaneously discounting the binary risk. The entire enterprise trades at roughly one quarter's operating loss—a classic "option" on the CLL catalyst. The company's BTK inhibitor combination thesis is unique in the space: no other drug blocks the TLR pathway. But the PCNSL program, while registrational, is a tiny market. CLL is the prize. If the dual blockade can convert PRs to CRs, even at a modest rate, the upside is enormous. If not, this micro-cap could face a desperate capital situation. Investors should watch for the fifth-patient announcement and the December data with a clear eye on the cash runway. The next five months will test both execution and market patience.